What is Palisade Bio, Inc. (PALI) stock price today?

Palisade Bio, Inc. (PALI) is currently trading at $1.54, up 6.21% today.

What is PALI P/E ratio?

Palisade Bio, Inc.'s P/E ratio is -2.71. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is PALI return on equity (ROE)?

Palisade Bio, Inc.'s return on equity (ROE) is -33.47%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Palisade Bio, Inc.'s market cap?

Palisade Bio, Inc. has a market capitalization of $267.31M.

NASDAQ · Biotechnology

Palisade Bio, Inc. (PALI) Stock

$1.54 +6.21% NASDAQ: PALI Healthcare

Valuation

Metric	Value
Price	$1.54
Market Cap	$267.31M
P/E Ratio	-2.71
P/B Ratio	2.50
P/S Ratio	499.91
EPS (TTM)	$-0.30
52-Week High	$2.86
52-Week Low	$1.32
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-33.47%
ROA	-25.09%
ROCE	-28.96%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.00
Current Ratio	26.80

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-42.0M	$-16.0M	$-13.0M	$-15.0M	$-18.0M
Net Profit	$-27.0M	$-14.0M	$-12.0M	$-14.0M	$-17.0M
EPS	$-2546.10	$-16.53	$-27.01	$-10.19	$-0.30
Op Margin	—	—	-5228.0%	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$13.0M	$16.0M	$14.0M	$11.0M	$134.0M
Total Liabilities	$5.0M	$3.0M	$3.0M	$3.0M	$5.0M
Cash	$10.0M	$12.0M	$12.0M	$10.0M	$133.0M
Borrowings	$0	$0	$0	$0	$0

Latest News

Palisade Bio to Participate in the Leerink Partners Therapeutics Forum GlobeNewswire · Jul 10, 2026 PALI Stock Heads For Best Day In Seven Months – What’s Driving Today’s Rally? Stocktwits · Jun 29, 2026 Palisade Bio Gets FDA IND Clearance for Phase 2 PALI-2108 UC Study MT Newswires · Jun 29, 2026 Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis GlobeNewswire · Jun 29, 2026 Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors GlobeNewswire · Jun 11, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-15.0M	$-13.0M	$-11.0M	$-12.0M	$-11.0M
Investing Cash Flow	$0	$0	$0	$0	$0
Financing Cash Flow	$0	$2.0M	$2.0M	$2.0M	$0
Net Cash Flow	$10.0M	$2.0M	$0	$-3.0M	$124.0M
Free Cash Flow	$-15.0M	$-13.0M	$-11.0M	$-12.0M	$-11.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-0.01
EV / EBITDA	-3.76
FCF Yield	-7.28%
Quick Ratio	24.26
Interest Coverage	-5891.50
Return 1Y	65.57%
Return 3Y	-93.74%
Return 5Y	-99.93%

Ownership

Insiders Held1.64%

Institutions Held96.11%

Institutions Float Held97.70%

Institutional Holder	Shares	Report Date
Ameriprise Financial, Inc.	11,510,320	2026-03-31
B Group, Inc.	11,414,285	2026-03-31
Janus Henderson Group PLC	10,689,452	2026-03-31
Octagon Capital Advisors LP	10,276,317	2026-03-31
Perceptive Advisors Llc	8,928,149	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ASBPAspire-Lakewood Holdings, Inc.	$8.30	+0.00%	-1.09	$957588	0.00%
ATHAAthira Pharma, Inc.	$6.75	-6.12%	-0.28	$26.62M	0.00%
BCTXBriaCell Therapeutics Corp.	$3.91	-0.26%	-0.33	$34.02M	0.00%
CRISCuris, Inc.	$0.67	-5.38%	-0.06	$1.31M	0.00%
CTXRCitius Pharmaceuticals, Inc.	$0.50	+2.19%	-0.25	$13.71M	0.00%

About Palisade Bio, Inc.

Palisade Bio, Inc. is led by CEO J. D. Finley, employs 8 people, headquartered in US, publicly traded since 2007.

Palisade Bio, Inc. (PALI) stock trades at $1.54 with a market capitalization of $267.31M. The stock is valued at a price-to-earnings (P/E) ratio of -2.71, price-to-book of 2.50, price-to-sales of 499.91. Over the past 52 weeks the stock has ranged between $1.32 and $2.86, and currently trades 46.2% below its 52-week high.

On profitability, Palisade Bio, Inc. generates a return on equity (ROE) of -33.47%, return on capital employed of -28.96%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides